首页> 外文期刊>Malaria Journal >Spread of anti-malarial drug resistance: Mathematical model with implications for ACT drug policies
【24h】

Spread of anti-malarial drug resistance: Mathematical model with implications for ACT drug policies

机译:抗疟疾药物耐药性传播:对ACT药物政策有影响的数学模型

获取原文
           

摘要

Background Most malaria-endemic countries are implementing a change in anti-malarial drug policy to artemisinin-based combination therapy (ACT). The impact of different drug choices and implementation strategies is uncertain. Data from many epidemiological studies in different levels of malaria endemicity and in areas with the highest prevalence of drug resistance like borders of Thailand are certainly valuable. Formulating an appropriate dynamic data-driven model is a powerful predictive tool for exploring the impact of these strategies quantitatively. Methods A comprehensive model was constructed incorporating important epidemiological and biological factors of human, mosquito, parasite and treatment. The iterative process of developing the model, identifying data needed, and parameterization has been taken to strongly link the model to the empirical evidence. The model provides quantitative measures of outcomes, such as malaria prevalence/incidence and treatment failure, and illustrates the spread of resistance in low and high transmission settings. The model was used to evaluate different anti-malarial policy options focusing on ACT deployment. Results The model predicts robustly that in low transmission settings drug resistance spreads faster than in high transmission settings, and treatment failure is the main force driving the spread of drug resistance. In low transmission settings, ACT slows the spread of drug resistance to a partner drug, especially at high coverage rates. This effect decreases exponentially with increasing delay in deploying the ACT and decreasing rates of coverage. In the high transmission settings, however, drug resistance is driven by the proportion of the human population with a residual drug level, which gives resistant parasites some survival advantage. The spread of drug resistance could be slowed down by controlling presumptive drug use and avoiding the use of combination therapies containing drugs with mismatched half-lives, together with reducing malaria transmission through vector control measures. Conclusion This paper has demonstrated the use of a comprehensive mathematical model to describe malaria transmission and the spread of drug resistance. The model is strongly linked to the empirical evidence obtained from extensive data available from various sources. This model can be a useful tool to inform the design of treatment policies, particularly at a time when ACT has been endorsed by WHO as first-line treatment for falciparum malaria worldwide.
机译:背景技术大多数疟疾流行国家正在实施基于青蒿素的联合治疗(ACT)的抗疟疾药物政策变更。不同药物选择和实施策略的影响尚不确定。来自许多流行病学研究的数据在不同程度的疟疾流行和泰国等泰国耐药性最高的地区肯定是有价值的。制定适当的动态数据驱动模型是一种强大的预测工具,可以定量地探索这些策略的影响。方法构建一个综合模型,综合考虑人,蚊,寄生虫和治疗的重要流行病学和生物学因素。开发模型,识别所需数据和进行参数化的迭代过程已将模型与经验证据紧密地联系在一起。该模型提供了诸如疟疾患病率/发病率和治疗失败等结局的定量指标,并说明了在低和高传播环境中耐药性的扩散。该模型用于评估针对ACT部署的不同反疟疾政策选择。结果该模型有力地预测,在低传播环境中,耐药性的传播要快于在高传播环境中,并且治疗失败是驱动耐药性传播的主要力量。在低传播条件下,ACT会减慢耐药性向伴侣药物的传播,尤其是在高覆盖率的情况下。随着部署ACT的延迟增加和覆盖率降低,这种影响呈指数下降。但是,在高传播环境中,耐药性是由人口中具有残留药物水平的人群所驱动,这使耐药性寄生虫具有一定的生存优势。可以通过控制假定的药物使用并避免使用包含半衰期不匹配的药物的联合疗法,并通过媒介控制措施减少疟疾的传播,来减慢耐药性的传播。结论本文证明了使用综合数学模型描述疟疾传播和耐药性传播。该模型与从各种来源获得的大量数据获得的经验证据密切相关。该模型可以成为指导治疗政策设计的有用工具,尤其是在世界卫生组织已将ACT视为全球恶性疟疾的一线治疗方法的时候。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号